You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Medtronic
Express Scripts
McKinsey
Johnson and Johnson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COSENTYX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for COSENTYX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02592018 Immunologic Response to Secukinumab in Plaque Psoriasis Recruiting Novartis Pharmaceuticals Phase 4 2016-07-01 This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.
NCT02592018 Immunologic Response to Secukinumab in Plaque Psoriasis Recruiting University of California, San Francisco Phase 4 2016-07-01 This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.
NCT02778711 Anti-IL-17 a New Treatment for Contact Dermatititis Recruiting Tanja Todberg, MD Phase 3 2016-01-01 The purpose of this study is to assess the efficacy of anti-IL 17 treatment (secukinumab) in patients with known severe allergic contact dermatitis (ACD).
NCT02854163 Effect of Secukinumab in the Treatment of Psoriatic Arthritis Recruiting Novartis Phase 2 2016-10-01 The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab, with respect to efficacy and adverse events. The results of this secondary exploratory analysis will inform the design of a larger, definitive study.
NCT02854163 Effect of Secukinumab in the Treatment of Psoriatic Arthritis Recruiting University of Liverpool Phase 2 2016-10-01 The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab, with respect to efficacy and adverse events. The results of this secondary exploratory analysis will inform the design of a larger, definitive study.
NCT03041038 The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Recruiting Icahn School of Medicine at Mount Sinai Phase 2 2016-12-01 The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. There are no therapies based on growing understanding of what causes the disease. However, there have been recent discoveries of marked elevations in expression of interleukin-17A (IL-17A) and IL-17-related cytokines in the skin of individuals with ichthyosis, which may explain the inflammation. Investigators propose that IL-17-targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for COSENTYX

Condition Name

Condition Name for COSENTYX
Intervention Trials
Psoriasis 6
Psoriatic Arthritis 2
Psoriasis Vulgaris 2
Lamellar Ichthyosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for COSENTYX
Intervention Trials
Psoriasis 7
Dermatitis, Exfoliative 2
Arthritis, Psoriatic 2
Arthritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for COSENTYX

Trials by Country

Trials by Country for COSENTYX
Location Trials
United States 32
Germany 4
France 2
Canada 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for COSENTYX
Location Trials
New York 4
Florida 2
Illinois 2
California 2
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for COSENTYX

Clinical Trial Phase

Clinical Trial Phase for COSENTYX
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for COSENTYX
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for COSENTYX

Sponsor Name

Sponsor Name for COSENTYX
Sponsor Trials
Novartis 4
Novartis Pharmaceuticals 4
Guangdong Provincial Hospital of Traditional Chinese Medicine 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for COSENTYX
Sponsor Trials
Other 17
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
McKinsey
Johnson and Johnson
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.